Souraya Sayegh

Souraya Sayegh

Auto-generated profile, based on publicly available information

Souraya Sayegh

Division of Medicine University College London London UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Aging Cell
Verified
Journal Article
Open access
SSSouraya Sayegh
Souraya Sayegh
CFCarlos Henrique Fantecelle
Carlos Henrique Fantecelle
PLPhatthamon Laphanuwat
Phatthamon Laphanuwat
PSPriya Subramanian
Priya Subramanian
MRMalcom H. A. Rustin
Malcom H. A. Rustin
ECEmma S. Chambers
Emma S. Chambers
Vitamin D 3 replacement in older insufficient adults significantly improves their antigen‐specific varicella zoster virus (VZV) cutaneous immunity. However, the mechanisms involved in this enhancement of cutaneous immunity are not known. Here, we show for the first time that vitamin D 3 blocks the senescence‐associated secretory phenotype (SASP) production by senescent fibroblasts by partially inhibiting the p38 MAPK pathway. Furthermore, transcriptomic analysis of skin biopsies from older subjects after vitamin D 3 supplementation shows that vitamin D 3 inhibits the same inflammatory pathways in response to saline as the specific p38 inhibitor, losmapimod, which also enhances immunity in the skin of older subjects. Vitamin D 3 supplementation therefore may enhance immunity during ageing in part by blocking p38 MAPK signalling and in turn inhibit SASP production from senescent cells in vivo.

17 October 2024 in Aging Cell
Verified
Journal Article
Open access
PSPriya Subramanian
Priya Subramanian
SSSouraya Sayegh
Souraya Sayegh
PLPhatthamon Laphanuwat
Phatthamon Laphanuwat
ODOliver P. Devine
Oliver P. Devine
CFCarlos Henrique Fantecelle
Carlos Henrique Fantecelle
AAArne N. Akbar
Arne N. Akbar
The integrated behaviour of multiple senescent cell types within a single human tissue leading to the development of malignancy is unclear. Patients with Familial Melanoma Syndrome (FMS) have heterozygous germline defects in the CDKN2A gene coding for the cyclin inhibitor p16INK4a. Melanocytes within skin biopsies from FMS patients express significantly less p16INK4a but express higher levels of the DNA‐damage protein 𝛾H2AX a than fibroblastic cells. However, patient fibroblasts also exhibit defects since senescent cells do not increase in the skin during ageing and fibroblasts isolated from the skin of patients have increased replicative capacity compared to control fibroblasts in vitro, culminating in abnormal nuclear morphology. Patient derived fibroblasts also secreted less SASP than control cells. Predisposition of FMS patients to melanoma may therefore result from integrated dysregulation of senescence in multiple cell types in vivo. The inherently greater levels of DNA damage and the overdependence of melanocytes on p16 for cell cycle inhibition after DNA damage makes them exquisitely susceptible to malignant transformation. This may be accentuated by senescence‐related defects in fibroblasts, in particular reduced SASP secretion that hinders recruitment of T cells in the steady state and thus reduces cutaneous immunosurveillance in vivo.

6 January 2026 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
LGLara Victoria Graham
Lara Victoria Graham
RFRussell B Foxall
Russell B Foxall
MAMargaret Ashton-Key
Margaret Ashton-Key
SKSalim I Khakoo
Salim I Khakoo
SSSouraya Sayegh
Souraya Sayegh
MBMatthew Blunt
Matthew Blunt
Autoreactive B cells that remain in lymphatic tissue after anti-CD20 antibody therapy are considered a major contributing factor to relapse in patients with autoimmune diseases. Natural killer (NK) cells contribute to the depletion of autoreactive B cells by anti-CD20 antibodies via antibody-dependent cellular cytotoxicity (ADCC). However, the impact of germinal centre–associated signals CD40 ligand (CD40L) and interleukin-4 (IL-4) on ADCC was unknown. This study used a combination of flow cytometry, immunohistochemistry, and ex vivo functional assays using peripheral blood mononuclear cells to investigate how CD40L and IL-4 affect NK cell–B cell interactions. CD40L and IL-4 significantly upregulate human leukocyte antigen (HLA)-E and total HLA Class I expression on the surface of B cells from healthy donors, as well as patients with rheumatoid arthritis and systemic lupus erythematosus. The upregulation of HLA-E and total HLA functions to inhibit B-cell depletion by NK cell–mediated ADCC induced by rituximab via NKG2A and killer cell immunoglobulin-like receptors (KIR). Moreover, B cells that have differentiated through the germinal centre have higher expression of HLA-E and total HLA compared with naive B cells and are more resistant to depletion by rituximab. In accordance with this, blockade of NKG2A and inhibitory KIRs by monalizumab and lirilumab, respectively, increased antibody-dependent cellular cytotoxicity against autologous B cells in vitro. Overall, this study identifies a novel mechanism of resistance of B cells to NK cell cytotoxicity and indicates that blockade of the HLA-E:NKG2A and HLA:KIR checkpoint axes could be beneficial for improving B-cell depletion in patients with autoimmune diseases.

4 April 2026
Verified
Thesis
Closed access
SSSouraya Sayegh
Souraya Sayegh
La polyarthrite rhumatoïde (PR) est une maladie auto-immune inflammatoire caractérisée par une synovite chronique aboutissant à la dégradation du cartilage et une érosion osseuse. Malgré la présence de stratégies thérapeutiques capables de contrôler la maladie, il n'existe aujourd'hui aucun traitement curatif. De nombreuses études ont déjà démontré les capacités immunomodulatrices des cellules souches mésenchymateuses dérivées du tissu adipeux (ADSC) in vitro et dans des modèles murins de PR. Cependant, cet effet n'a toujours pas été traduit efficacement dans un contexte clinique. L'objectif de cette étude est de définir comment l'inflammation pourrait dicter l'efficacité thérapeutique des ADSC par (i) une approche translationnelle en utilisant des liquides synoviaux (SF) de patients atteints de PR ou (ii) en étudiant l'effet des injections d'ADSC dans deux modèles différents d'arthrite expérimentale. Nous montrons que les SF pro-inflammatoires conservent la capacité des ADSC à proliférer ainsi que leur phénotype et induisent l'expression des gènes COX-2, IDO, IL-6, TSG6, ICAM-1, VCAM-1 and PD-L1 qui sont tous impliqués dans le potentiel immunomodulateur des ADSC. Nous démontrons que l'effet des SF est directement médié par la voie de signalisation TNF/NF-?B et partiellement par l'IL-6. De plus, le pré-traitement des ADSC avec les SF inflammatoires renforce leur capacité à moduler les marqueurs pro-inflammatoires des macrophages (CD40 et CD80) et à induire des lymphocytes T régulateurs (Tregs). In vivo, les ADSC injectées par voie intra-péritonéale ont aggravé la progression d'arthrite dans le modèle de transfert de sérum K/BxN en traitement préventif mais n'ont eu aucun effet sur les scores arthritiques en traitement thérapeutique. En outre, un effet protectif sur la progression de l'arthrite n'a été observé que lorsque les ADSC ont été injectées par voie intra-articulaire. L'ensemble de nos résultats mettent en avant l'influence de l'environnement inflammatoire local sur les effets thérapeutiques des ADSC et suggèrent leur adressage direct aux sites inflammatoires qui stimulent leur potentiel immunomodulateur et maximisent leur intérêt clinique.